Celgene Corporation Logo

E-mail this page: News Release

Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported

For security reasons, registration is required before you can use this feature.
* Indicates required field